期刊论文详细信息
| Alzheimer’s Research & Therapy | |
| Aducanumab produced a clinically meaningful benefit in association with amyloid lowering | |
| Cynthia Lemere1  Alireza Atri2  Stephen Salloway3  Jeffrey Cummings4  Marwan Sabbagh5  Paul Aisen6  | |
| [1] Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School;Banner Sun Health Research Institute, Banner Health;Butler Hospital and Brown University;Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV);Cleveland Clinic Lou Ruvo Center for Brain Health;University of Southern California; | |
| 关键词: Aducanumab; FDA; Clinical trials; Monoclonal antibodies; Lecanemab; Donanemab; | |
| DOI : 10.1186/s13195-021-00838-z | |
| 来源: DOAJ | |
【 授权许可】
Unknown